United Therapeutics Corporation (UTHR)

NASDAQ: UTHR · Real-Time Price · USD

578.54

+0.91 (0.16%)

At close: Apr 14, 2026, 4:00 PM EDT

578.54

0.00 (0.00%)

After-hours: Apr 14, 2026, 5:37 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Revenue	1.88B	1.62B
Tyvaso Revenue Growth	15.91%	31.34%
Remodulin Revenue	526.80M	538.10M
Remodulin Revenue Growth	-2.10%	8.75%
Orenitram Revenue	496.90M	434.30M
Orenitram Revenue Growth	14.41%	20.84%
Unituxin Revenue	226.80M	238.70M
Unituxin Revenue Growth	-4.98%	20.01%
Adcirca Revenue	30.00M	23.80M
Adcirca Revenue Growth	26.05%	-17.65%
Total Product Sales Revenue	3.16B	2.86B
Total Product Sales Revenue Growth	10.63%	23.30%
Revenue (Other)	24.00M	22.10M
Revenue (Total)	3.18B	2.88B
Revenue (Total) Growth	10.61%	23.63%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	3.04B	2.74B
United States Revenue Growth	10.85%	24.41%
Rest-of-World Revenue	145.70M	137.70M
Rest-of-World Revenue Growth	5.81%	9.90%
Revenue (Total)	3.18B	2.88B
Revenue (Total) Growth	10.61%	23.63%

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Tyvaso Gross Profit	1.64B	1.44B
Tyvaso Gross Profit Growth	14.08%	32.44%
Remodulin Gross Profit	477.50M	490.70M
Remodulin Gross Profit Growth	-2.69%	7.47%
Orenitram Gross Profit	468.20M	405.90M
Orenitram Gross Profit Growth	15.35%	21.09%
Unituxin Gross Profit	209.30M	224.30M
Unituxin Gross Profit Growth	-6.69%	22.97%
Adcirca Gross Profit	16.90M	13.70M
Adcirca Gross Profit Growth	23.36%	-17.47%
Total Product Sales Gross Profit	2.81B	2.57B
Total Product Sales Gross Profit Growth	9.32%	23.89%
Gross Profit (Other)	-14.00M	-4.80M
Gross Profit (Total)	2.80B	2.57B
Gross Profit (Total) Growth	8.98%	24.04%

Updated Feb 25, 2026. Data Source: Fiscal.ai.